NEWS FROM THE STANDARD |
 |
Biotech: Desperate No More
Jun 27 2001 07:21 AM PDT
PROFILE |
 |
Diversa searches high and low for DNA. In its quest to develop new enzymes and other active biological compounds, the firm collects and catalogs the DNA of organisms in diverse environments (including manure piles, industrial waste sites, Antarctic valleys, and tropical Bermuda,). Companies license these compounds to develop or improve their products, which include detergents, oils, animal feeds, and pharmaceuticals. Diversa's first product is Pyrolase 160, an enzyme for the oil and gas industry. Company partners include a unit of Aventis, Dow Chemical, and Syngenta, the agrochemicals spinoff of Novartis and AstraZeneca. Venture capital firms Healthcare Ventures and Patricof & Co. each own about 15% of Diversa.
COMPETITION |
 |
ArQule, Inc. (ARQL)
Genencor International, Inc. (GCOR)
Maxygen, Inc. (MAXY)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 24.30
1-Yr. Sales Growth: 135.9%
Employees: 200
Revenue per employee: $121,500.00
KEY PEOPLE |
 |
Jay M. Short
CEO
Karin Eastham
CFO
CONTACT INFO |
 |
4955 Directors Place
San Diego, CA 92121
US
Phone: 858-526-5000
Fax: 858-526-5551
Online: Web Site
|